{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:40Z","timestamp":1790192800140,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836031008"],"award-info":[{"award-number":["836031008"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ekir.2022.10.013","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T04:57:19Z","timestamp":1666069039000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Romy N.","family":"Bouwmeester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Duineveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kioa L.","family":"Wijnsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike J.","family":"Bemelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost W.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna A.E.","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia H.M.","family":"Bouts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiske","family":"Dorresteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan P.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan D.","family":"van Zuilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy G.","family":"Keijzer-Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko P.J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos W.G.","family":"van Rooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flore A.P.T.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evy","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy M.","family":"Adang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendy","family":"ter Avest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P.W.J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.10.013_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.10.013_bib2","first-page":"121","article-title":"A\u00a0new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome","volume":"70","author":"Westra","year":"2012","journal-title":"Neth J Med"},{"key":"10.1016\/j.ekir.2022.10.013_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 4","key":"10.1016\/j.ekir.2022.10.013_bib6","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1093\/ndt\/gfu235","article-title":"Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab","volume":"29","author":"Verhave","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.10.013_bib7","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.10.013_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: state of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2022.10.013_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2022.10.013_bib10","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2022.10.013_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.10.013_bib12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2022.10.013_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.10.013_bib14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2022.10.013_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.kint.2021.02.033","article-title":"Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome","volume":"100","author":"Bouwmeester","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.10.013_bib16","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ekir.2022.10.013_bib17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ekir.2022.10.013_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.ekir.2022.10.013_bib19","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib20","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/cpt.686","article-title":"Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment","volume":"102","author":"Volokhina","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2022.10.013_bib23","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib24","first-page":"1574","article-title":"Kwaliteit van leven meten in economische evaluaties: het Nederlands EQ-5D-tarief","volume":"149","author":"Lamers","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.ekir.2022.10.013_bib25","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/ckj\/sfaa241","article-title":"Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal","volume":"14","author":"Duineveld","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2022.10.013_bib26","first-page":"27","article-title":"A\u00a0national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"Q\u00a0J M"},{"key":"10.1016\/j.ekir.2022.10.013_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.10.013_bib28","first-page":"1213","article-title":"Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study","volume":"35","author":"Baskin","year":"2022","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib30","first-page":"127","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle","year":"2017","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","article-title":"Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome","volume":"65","author":"Bu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.10.013_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2022.10.013_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.10.013_bib34","first-page":"1373","article-title":"Eculizumab interruption in atypical hemolytic uremic syndrome due to shortage: analysis of a Brazilian cohort","volume":"34","author":"Neto","year":"2021","journal-title":"J\u00a0Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922018265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922018265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:47:44Z","timestamp":1762832864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922018265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2468024922018265"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.10.013","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.11.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}